Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC).

Abstract

3047 Background: MEDI4736 is a human IgG1 monoclonal antibody which blocks PD-L1 binding to PD-1 and CD-80 with high affinity and selectivity. A Phase I open-label multicenter study was initiated t...